Payment overview · 2025
General Payments
$569.42
37 reported records · 10 companies
Healthcare provider profile · identity verified
Jeffrey D. Hamby, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · VAN BUREN, AR · NPI 1831178524
Verified facts
What the public records show
CMS Open Payments records show Jeffrey D. Hamby, M.D. received $569.42 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $188.65 | 33.1% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $150.81 | 26.5% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.03 | 10.9% | 4 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $45.86 | 8.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.17 | 6.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.80 | 3.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.63 | 3.5% | 1 | 2025 |
| Hikma Pharmaceuticals USA | Unresolved — no canonical attribution shown | $19.00 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.63 | 2.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.84 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $569.42 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $150.81 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $100.70 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $87.95 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.03 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.03 | 4 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $45.86 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| Ryaltris Normalized: ryaltris |
Drug | Hikma Pharmaceuticals USA | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 169 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
131 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 711 | 120 |
| Atorvastatin Calcium | Atorvastatin Calcium | 559 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 535 | 151 |
| Omeprazole | Omeprazole | 463 | 135 |
| Losartan Potassium | Losartan Potassium | 444 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 85 |
| Alprazolam | Alprazolam | 327 | 51 |
| Lisinopril | Lisinopril | 299 | 86 |
| Tramadol Hcl | Tramadol Hcl | 275 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 77 |
| Carvedilol | Carvedilol | 217 | 67 |
| Metformin Hcl | Metformin Hcl | 200 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 69 |
| Gabapentin | Gabapentin | 190 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 185 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 57 |
| Ozempic | Semaglutide | 169 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 60 |
| Meloxicam | Meloxicam | 139 | 45 |
| Eliquis | Apixaban | 138 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 137 | 40 |
| Clonazepam | Clonazepam | 131 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 37 |
| Farxiga | Dapagliflozin Propanediol | 131 | 33 |
| Nebivolol Hcl | Nebivolol Hcl | 129 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 47 |
| Azithromycin | Azithromycin | 127 | 110 |
| Furosemide | Furosemide | 114 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 39 |
| Montelukast Sodium | Montelukast Sodium | 107 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 95 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 28 |
| Celecoxib | Celecoxib | 90 | 32 |
| Potassium Chloride | Potassium Chloride | 90 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 29 |
| Clonidine Hcl | Clonidine Hcl | 86 | 29 |
| Aripiprazole | Aripiprazole | 85 | 20 |
| Simvastatin | Simvastatin | 82 | 23 |
| Ondansetron Odt | Ondansetron | 81 | 36 |
| Prednisone | Prednisone | 77 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 17 |
| Estradiol | Estradiol | 74 | 23 |
| Spironolactone | Spironolactone | 74 | 20 |
| Levofloxacin | Levofloxacin | 73 | 62 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 20 |
| Sertraline Hcl | Sertraline Hcl | 62 | 15 |
| Warfarin Sodium | Warfarin Sodium | 62 | 15 |
| Nitroglycerin | Nitroglycerin | 61 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 13 |
| Pregabalin | Pregabalin | 57 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 47 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 54 | 12 |
| Trazodone Hcl | Trazodone Hcl | 53 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | 13 |
| Lorazepam | Lorazepam | 49 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 14 |
| Fluconazole | Fluconazole | 45 | 31 |
| Finasteride | Finasteride | 42 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 13 |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 13 |
| Olanzapine | Olanzapine | 39 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 26 |
| Cephalexin | Cephalexin | 32 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 11 |
| Atenolol | Atenolol | 31 | suppressed |
| Movantik | Naloxegol Oxalate | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 27 | suppressed |
| Glipizide | Glipizide | 27 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | 12 |
| Temazepam | Temazepam | 26 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Famotidine | Famotidine | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Uloric | Febuxostat | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $569.42 · 37 records | ABBVIE INC. | Auvelity, Azstarys, BREZTRI, CAPLYTA, FANAPT, HETLIOZ, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Ryaltris, Rybelsus, SYNTHROID, UBRELVY, VRAYLAR, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error